Disease · MONDO_0005164

fibrosarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. fibrosarcoma. Diseases, record MONDO_0005164. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005164

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: fibrosarcoma; Open Targets
Open Targets ID: MONDO_0005164; Open Targets
Other names: fibrocytic tumor, fibrosarcoma (disease), fibrosarcoma (excluding infantile fibrosarcoma), fibrosarcoma - not infantile, fibrosarcoma of soft tissue, fibrosarcoma, malignant, fibrous tissue neoplasm, malignant fibromatous neoplasm; Open Targets
Disease Ontology: DOID:3355; Disease Ontology
MeSH: D005354; MeSH
NCI Thesaurus: C3043; NCI Thesaurus
Orphanet: ORPHA:2030; Orphanet
Highest stage of its drugs: Phase 2, for 9 of its 12 drugs, from ClinicalTrials.gov; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LAROTRECTINIB	CHEMBL3889654	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DACTINOMYCIN	CHEMBL1554	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IMATINIB MESYLATE	CHEMBL1642	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PELAREOREP	CHEMBL3545069		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SUNITINIB MALATE	CHEMBL1567	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets43

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KIT	Mast/stem cell growth factor receptor Kit	3	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	3	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
ABL1	Bcr/Abl fusion protein	2	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
NTRK1	High affinity nerve growth factor receptor	2	Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor inhibitor	Phase 2	https://conductscience.org/library/genes/4914	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5156	Drugs and targets
RET	Proto-oncogene tyrosine-protein kinase receptor Ret	2	Tyrosine-protein kinase receptor RET inhibitor	Phase 2	https://conductscience.org/library/genes/5979	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets

1 to 10 of 43

See all 43 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05236257	A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database		93	2024-12-10	Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion, Infantile Fibrosarcoma	LAROTRECTINIB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00400569	Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma	Phase 2	48	2012-08-28	Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Malignant Fibrous Histiocytoma	SUNITINIB MALATE	Its record names the disease	ClinicalTrials.gov
NCT03834961	Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia	Phase 2	33	2025-12-02	Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia, Solid Neoplasm	LAROTRECTINIB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00072280	Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma	Phase 2	7	2013-11-26	Sarcoma	CYCLOPHOSPHAMIDE, DACTINOMYCIN, ETOPOSIDE, IFOSFAMIDE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00154388	Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases	Phase 2	185		Life Threatening Diseases	IMATINIB MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT04055220	Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas	Not applicable	168		Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Angiosarcoma	REGORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT02637687	A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children	Phase 1/2	154		Solid Tumors Harboring NTRK Fusion	LAROTRECTINIB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00503295	Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung	Phase 2	53		Osteosarcoma, Ewing Sarcoma Family Tumors, Malignant Fibrous Histiocytoma, Sarcoma, Synovial, Fibrosarcoma, Leiomyosarcoma	PELAREOREP	Its record names the disease	ClinicalTrials.gov
NCT01837667	Phase I Study of LB-100 With Docetaxel in Solid Tumors	Phase 1	29		Tumors, Neoplasms, Cancer	DOCETAXEL, LB-100	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Larotrectinib vs External Controls: deaths from any cause	1 of 51	3 of 42	93	NCT05236257	Trial comparisons
Larotrectinib vs External Controls: Number of Participants With Treatment Discontinuation Due to Treatment Emergent Adverse Events	0 of 51	1 of 42	93	NCT05236257	Trial comparisons
Larotrectinib vs External Controls: serious adverse events	1 of 51	3 of 42	93	NCT05236257	Trial comparisons
Chemotherapy Plus Possible Surgery vs Surgery Only: serious adverse events	0 of 2	0 of 2	4	NCT00072280	Trial comparisons

Papers from its trials22

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28039265	RESULT	1	PubMed
19451433	RESULT	1	PubMed
42614029	DERIVED	1	PubMed
40341199	DERIVED	1	PubMed
40267388	DERIVED	1	PubMed
39869835	DERIVED	1	PubMed
39652801	DERIVED	1	PubMed
38096907	DERIVED	1	PubMed
37934000	DERIVED	1	PubMed
37769113	DERIVED	1	PubMed

1 to 10 of 22

See all 22 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005164

GET https://conductscience.org/api/diseases/v1/MONDO_0005164/targets?page=2

API reference For AI assistants